CA1050535A - 9,3",4"-triacyl ester of the antibiotic sf-837 m1 substance and the production thereof - Google Patents
9,3",4"-triacyl ester of the antibiotic sf-837 m1 substance and the production thereofInfo
- Publication number
- CA1050535A CA1050535A CA234,025A CA234025A CA1050535A CA 1050535 A CA1050535 A CA 1050535A CA 234025 A CA234025 A CA 234025A CA 1050535 A CA1050535 A CA 1050535A
- Authority
- CA
- Canada
- Prior art keywords
- substance
- acetyl
- propionyl
- alkanoyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000126 substance Substances 0.000 title claims abstract description 323
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 150000002148 esters Chemical class 0.000 title abstract description 5
- GNXVPSYTTPBCTM-RQWHEHCQSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] pr Chemical compound CO[C@H]1[C@H](OC(=O)CC)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 GNXVPSYTTPBCTM-RQWHEHCQSA-N 0.000 title 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 32
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 71
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 65
- -1 n-butyryl Chemical group 0.000 claims description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 43
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 150000008065 acid anhydrides Chemical class 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000006460 hydrolysis reaction Methods 0.000 claims description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 150000007530 organic bases Chemical class 0.000 claims description 11
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 claims description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 241000192125 Firmicutes Species 0.000 abstract description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 83
- 239000000047 product Substances 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 47
- 239000000243 solution Substances 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- 238000005917 acylation reaction Methods 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- 230000010933 acylation Effects 0.000 description 18
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000007062 hydrolysis Effects 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- 150000008064 anhydrides Chemical class 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000786363 Rhampholeon spectrum Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- FREZLSIGWNCSOQ-UHFFFAOYSA-N 3-methylbutanoyl 3-methylbutanoate Chemical compound CC(C)CC(=O)OC(=O)CC(C)C FREZLSIGWNCSOQ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000984642 Cura Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP49097485A JPS5126887A (en) | 1974-08-27 | 1974-08-27 | Koseibutsushitsu sff837m1 butsushitsuno 9*3**4* toriashirujudotaino seizoho |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1050535A true CA1050535A (en) | 1979-03-13 |
Family
ID=14193562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA234,025A Expired CA1050535A (en) | 1974-08-27 | 1975-08-25 | 9,3",4"-triacyl ester of the antibiotic sf-837 m1 substance and the production thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4017607A (en, 2012) |
| JP (1) | JPS5126887A (en, 2012) |
| AR (1) | AR205581A1 (en, 2012) |
| AT (1) | AT345981B (en, 2012) |
| BE (1) | BE832813A (en, 2012) |
| CA (1) | CA1050535A (en, 2012) |
| CH (1) | CH629820A5 (en, 2012) |
| DE (1) | DE2537375C3 (en, 2012) |
| DK (1) | DK141170B (en, 2012) |
| ES (1) | ES440525A1 (en, 2012) |
| FR (1) | FR2282903A1 (en, 2012) |
| GB (1) | GB1520145A (en, 2012) |
| HU (1) | HU175793B (en, 2012) |
| IL (1) | IL47753A (en, 2012) |
| NL (1) | NL167969B (en, 2012) |
| SE (1) | SE429237B (en, 2012) |
| ZA (1) | ZA754685B (en, 2012) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5432493A (en) * | 1977-08-15 | 1979-03-09 | Meiji Seika Kaisha Ltd | Preparation of macrolide antibiotics derivatives |
| SE445556B (sv) * | 1978-05-10 | 1986-06-30 | Toyo Jozo Kk | Nya 3"-acylerade makrolidantibiotika |
| JPS618575Y2 (en, 2012) * | 1978-05-24 | 1986-03-17 | ||
| JPS5517997U (en, 2012) * | 1978-07-22 | 1980-02-05 | ||
| SE445739B (sv) * | 1978-09-14 | 1986-07-14 | Toyo Jozo Kk | 3", 4"-diacyltylosinderivat |
| US4438109A (en) | 1980-07-25 | 1984-03-20 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Tylosin derivatives |
| JPS5894804U (ja) * | 1981-12-21 | 1983-06-27 | 日本車輌製造株式会社 | 産業機械の内燃機関の潤滑油排出装置 |
| US4851518A (en) * | 1985-12-23 | 1989-07-25 | Schering Corporation | Di and tri-O-acetyl-"O-iso-valeryl-23-O-demycinosyl tylosins, hydrazone derivatives thereof and processes for their preparation |
| JPS62242694A (ja) * | 1986-04-15 | 1987-10-23 | Toyo Jozo Co Ltd | ２０−０−アシル−１９，２０−エノ−ルマクロライド系抗生物質誘導体 |
| ES2131549T3 (es) * | 1992-10-29 | 1999-08-01 | Meiji Seika Kaisha | Derivados macrolidas de 16 eslabones y su procedimiento de preparacion. |
| CN102775456A (zh) * | 2011-05-13 | 2012-11-14 | 北大方正集团有限公司 | 一种制备乙酰麦迪霉素的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH80A (fr) * | 1889-01-09 | Henri Sandoz | Ecrin à détente pour montres à répétition | |
| CH83A (fr) * | 1888-11-17 | 1889-01-10 | Fontainemelon Horlogerie | Perfectionnements apportés à la construction des montres de tous calibres |
| US3792035A (en) * | 1970-05-04 | 1974-02-12 | Meiji Seika Kaisha | Mono-acetyl derivatives of antibiotic sf-837 and sf-837-a2 substances and production thereof |
| FI56187C (fi) * | 1970-07-02 | 1979-12-10 | Takeda Chemical Industries Ltd | Foerfarande foer framstaellning av antibiotiskt aktiva estrar av makrolidglykosiderna b-5050 eller tetrahydro b-5050 |
| JPS4836218A (en, 2012) * | 1971-09-10 | 1973-05-28 | ||
| US3855202A (en) * | 1972-06-15 | 1974-12-17 | Meiji Seika Kaisha | One step process for the production of a monoester of macrolide antibiotics |
-
1974
- 1974-08-27 JP JP49097485A patent/JPS5126887A/ja active Granted
-
1975
- 1975-01-01 AR AR260046A patent/AR205581A1/es active
- 1975-07-18 US US05/597,188 patent/US4017607A/en not_active Expired - Lifetime
- 1975-07-18 DK DK327375AA patent/DK141170B/da not_active IP Right Cessation
- 1975-07-21 ZA ZA00754685A patent/ZA754685B/xx unknown
- 1975-07-21 IL IL47753A patent/IL47753A/xx unknown
- 1975-07-22 GB GB30518/75A patent/GB1520145A/en not_active Expired
- 1975-08-22 DE DE2537375A patent/DE2537375C3/de not_active Expired
- 1975-08-25 HU HU75ME1887A patent/HU175793B/hu unknown
- 1975-08-25 CA CA234,025A patent/CA1050535A/en not_active Expired
- 1975-08-26 FR FR7526216A patent/FR2282903A1/fr active Granted
- 1975-08-27 CH CH1110075A patent/CH629820A5/de not_active IP Right Cessation
- 1975-08-27 NL NL7510139.A patent/NL167969B/xx not_active IP Right Cessation
- 1975-08-27 SE SE7509524A patent/SE429237B/xx not_active IP Right Cessation
- 1975-08-27 ES ES440525A patent/ES440525A1/es not_active Expired
- 1975-08-27 BE BE159524A patent/BE832813A/xx not_active IP Right Cessation
- 1975-08-27 AT AT662375A patent/AT345981B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2282903B1 (en, 2012) | 1978-11-10 |
| NL167969B (nl) | 1981-09-16 |
| DK141170C (en, 2012) | 1980-07-21 |
| IL47753A (en) | 1978-04-30 |
| ZA754685B (en) | 1976-06-30 |
| GB1520145A (en) | 1978-08-02 |
| AT345981B (de) | 1978-10-10 |
| IL47753A0 (en) | 1975-10-15 |
| JPS5512040B2 (en, 2012) | 1980-03-29 |
| AU8352575A (en) | 1977-02-03 |
| JPS5126887A (en) | 1976-03-05 |
| HU175793B (hu) | 1980-10-28 |
| DE2537375C3 (de) | 1979-10-25 |
| CH629820A5 (en) | 1982-05-14 |
| BE832813A (fr) | 1975-12-16 |
| SE7509524L (sv) | 1976-03-01 |
| DK327375A (en, 2012) | 1976-02-28 |
| ES440525A1 (es) | 1977-06-16 |
| DK141170B (da) | 1980-01-28 |
| DE2537375A1 (de) | 1976-03-11 |
| AR205581A1 (es) | 1976-05-14 |
| SE429237B (sv) | 1983-08-22 |
| US4017607A (en) | 1977-04-12 |
| NL7510139A (nl) | 1976-03-02 |
| FR2282903A1 (fr) | 1976-03-26 |
| ATA662375A (de) | 1978-02-15 |
| DE2537375B2 (de) | 1979-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK172636B1 (en) | 6-o-methylerythromycin a derivative | |
| US4331803A (en) | Novel erythromycin compounds | |
| CA1117046A (en) | Organic compounds | |
| ES2242668T3 (es) | Metodo para obtener claritromicina en cristales de forma ii. | |
| CA1050535A (en) | 9,3",4"-triacyl ester of the antibiotic sf-837 m1 substance and the production thereof | |
| MORIMOTO et al. | Chemical modification of erythromycins II. Synthesis and antibacterial activity of O-alkyl derivatives of erythromycin A | |
| SE457084B (sv) | N-metyl-11-aza-10-deoxo-10-dihydroerytromycin a och derivat samt foerfarande foer framstaellning daerav | |
| KR850000965B1 (ko) | 4"-에피 에리스로마이신 a 및 그의 유도체의 제조방법 | |
| JPH09151187A (ja) | ４′−デメチルエピポドフィロトキシン誘導体 | |
| FI110782B (fi) | Demetyyliepipodofyllotoksiini-beeta-D-glukosidit, menetelmä niiden valmistamiseksi, beeta-D-glukoosijohdannaiset ja menetelmät demetyyliepipodofyllotoksiini-beeta-D-glukoosin dimeerien valmistamiseksi | |
| CA1154013A (en) | Antitumor glycosides, their preparation, use and compositions thereof | |
| IE50057B1 (en) | Paromomycin derivatives | |
| EP0259496B1 (en) | Derivatives of cervinomycin antibiotics and process for their preparation | |
| Morimoto et al. | Chemical modification of erythromycins VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A | |
| US4029881A (en) | Antibiotic 9-acyl-3"-thiomethoxymethyl-SF-837 composition and process for preparing the same | |
| US4242504A (en) | 3"-Acylated macrolide antibiotics | |
| US3428623A (en) | Coumarin derivatives | |
| Pérez et al. | Inhibitory activity of 3-methylenhydroxy-5-methoxy-2, 4-dihydroxy tetrahydrofurane isolated from Selaginella lepidophyla on smooth muscle of Wistar rat | |
| EP0490311B1 (en) | Derivatives of 10,11,12,13-tetra-hydrodesmycosin, processes for preparation, and use thereof in obtaining pharmaceuticals | |
| US3290284A (en) | Novel glycosides of desosamine | |
| GB2034707A (en) | Anthracycline glycosides | |
| KR800001568B1 (ko) | 항생물질 sf-837m_1의 9, 3˝,4˝-트리아실 유도체의 제조법 | |
| MUROI et al. | MARIDOMYCIN, A NEW MACROLIDE ANTIBIOTIC. VIII ISOLATION AND STRUCTURES OF METABOLITES OF 9-PROPIONYLMARIDOMYCIN | |
| CA1185968A (en) | Method of preparing 23-monoesters of omt and dmt | |
| US3959256A (en) | 9-O-Alkanoyl-3"-O-alkanoyloxymethyl-SF-837 substance and the production thereof |